Çocukluk çağı akut lenfoblastik lösemilerde serum Fas ve Fas Ligand düzeyleri

Amaç: Bu çalışmada, çocukluk çağı akut lenfoblastik lösemilerinde (ALL), apoptozis mekanizmasının anlaşılmasında rol oynayan hücre membran reseptörlerinden serum Fas ve Fas Ligand düzeyinin araştırılması amaçlanmıştır.Gereç ve Yöntem: Çocukluk çağı akut lenfoblastik lösemi tanısı (1-18 yaş) almış 29 hastada tanı anında periferik kandan elde edilen serum Fas ve Fas Ligand düzeyleri ELISA yöntemi ile çalışıldı. Yirmiyedi çocuktan oluşan kontrol grubunun yaş dağılımı 1-15 yıl arasındaydı. Bulgular: ALL‟li hastalarda serum Fas düzeyi ortanca 63 pg/mL (15-690 pg/mL) kontrol grubunda ortalama serum Fas düzeyi ortanca 37 pg/mL (8-67 pg/mL) saptandı. ALL‟li hastalarda serum Fas Ligand düzeyi ortanca 0,18 ng/mL (0-2,1 ng/mL), kontrol grubunda ise ortanca 0,1 ng/mL (0-4 ng/mL) saptandı. Akut lenfoblastik lösemi tanılı hastalar ile, kontrol grubu arasında ortalama serum Fas düzeyleri açısından istatistiksel olarak anlamlı fark varken, Fas Ligand düzeyleri arasında fark saptanmadı. Akut Lenfoblastik Lösemili hastalar immunfenotiplemeye göre serum Fas düzeyi karşılaştırıldığında T-ALL hastalarında B-ALL’li hastalara göre istatistiksel olarak anlamlı fark bulundu. Relaps olan hastalarda remisyondaki hastalara göre Fas düzeyleri anlamlı olarak yüksek saptandı. Sonuç: Bu bulgular sonucunda serum Fas düzeylerinin ALL hastalarda prognostik faktör olarak değerlendirilebileceği düşünüldü.

Anahtar Kelimeler:

akut lenfoblastik lösemi, Fas, Fas Ligand

Serum Fas and Fas Ligand levels in childhood acute lymphoblastic leukemias

Purpose: The aim of this study was to investigate the Fas and Fas Ligand levels of cell membrane receptors that play a role in understanding the mechanism of apoptosis in childhood acute lymphoblastic leukemia (ALL). Materials and Methods: We investigated serum Fas and Fas Ligand levels by using ELISA method in childhood acute leukemias. Twenty-nine cases with acute lymphoblastic leukemia and twenty-seven healthy children included the study. We investigated serum Fas and Fas Ligand levels at the time of diagnosis from peripheral blood samples. Results: Serum Fas levels of patients were median 63 pg/mL (min 15- max 690 pg/mL) and in the control group were median 37 pg/mL (min 8- max 67 pg/mL). Fas Ligand levels of patients were median 0.18 ng/mL (min 0- max 2.1 ng/mL) and in the control group median 0.1 ng/mL (min 0- max 4 ng/mL). The comparison of the mean values of Fas levels in acute leukemia patients groups and control group have shown important difference as statistically, but Fas Ligand levels were similar. Fas levels in T-ALL patients according to immunophenotypes were statistically higher than B-ALL . The Fas levels of patients who had relapsed were statistically higher than patients in remission. Conclusion: Serum Fas levels could be a useful prognostic marker in ALL patients follow up.

PDF

___

1. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Principles and Practice of Pediatric Oncology, 4th ed. (Eds Pizzo PA, Poplack DG):4890-544. Philadelphia: Lippincott Williams & Wilkins. 2002:489-544
2. Iannolo G, Conticello C, Memeo L, De Maria R. Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol. 2008;66:42–5.
3. Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S. Apoptosis as a mechanism of T– regulatory cell homeostasis and suppression apoptosis in T–regulatory cell homeostasis. Immunol Cell Biol. 2008;86:650–8.
4. Wickremasinghe RG, Hoffbrand AG. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies. Blood, 1999;93:3587-600.
5. Verlekar D, Wei1 SJ, Cho H, Yang S, Kang MH. Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia. Cell Death Dis. 2018;9:925.
6. Vitagliano O, Addeo R, D’Angelo V, Indolfi C, Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev. Hematol. 2013;6:587-97.
7. Letai A, Sorcinelli M, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6:241–9.
8. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111:2300–9.
9. Singh A, Bhatia P, Trehan A, Bansal D, Singh A, Bhatia A. Low spontaneous apoptosis index at diagnosis predicts a high-risk phenotype in paediatric acute lymphoblastic leukemia. Indian J Med Res. 2018;147:248-550.
10. Kaparou M, Choumerianou D, Perdikogianni C, Martimianaki G, Kalmanti M, Stiakak E. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features. Genet Mol Biol. 2013;36:7-11.
11. Hazar V, Berber Z, Pestereli E, Coskun M, Yesilipek A, Karpuzoglu G et al. Clinical importance of circulating and cellular expression levels of Fas and Fas Ligand in pediatric patients with lymphoproliferative malignancies. Pediatr Hematol Oncol. 2005;22:247-56.
12. Fathi M, Amirghofran Z, Shahriari. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol. 2002;29:2046- 52.
13. Karawajew L, Wuchter C, Ruppert V, Drexler H, Gruss HJ, DörkenB. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia.1997;11:1245-52.
14. Aref S, Salama O, Al-tonbary Y,Mansour A. Assesment of Bcl-2 expression as modulator of Fas mediated apoptosis in acute leukemia. Hematology. 2004;9:113-21.